MAPT and Alzheimer disease: As a result, the current AD diagnosis, as defined by the NIA-AA criteria, relies on a cognitive assessment (at least MCI) and the estimation of cerebral amyloid deposits (referred to as amyloid status) through amyloid PET scans or by determining Aβ42 and/or p-tau levels in the CSF (2, 3).